



**Universiteit
Leiden**
The Netherlands

Targeting integrins for cancer therapy - disappointments and opportunities

Bergonzini, C.; Kroese, K.; Zweemer, J.M.; Danen, E.H.J.

Citation

Bergonzini, C., Kroese, K., Zweemer, J. M., & Danen, E. H. J. (2022). Targeting integrins for cancer therapy - disappointments and opportunities. *Frontiers In Cell And Developmental Biology*, 10. doi:10.3389/fcell.2022.863850

Version: Publisher's Version

License: [Creative Commons CC BY 4.0 license](https://creativecommons.org/licenses/by/4.0/)

Downloaded from: <https://hdl.handle.net/1887/3420582>

Note: To cite this publication please use the final published version (if applicable).



Targeting Integrins for Cancer Therapy - Disappointments and Opportunities

Cecilia Bergonzini, Kim Kroese, Annelien J. M. Zweemer and Erik H. J. Danen *

Leiden Academic Center for Drug Research, Leiden University, Leiden, Netherlands

OPEN ACCESS

Edited by:

Andreja Ambriovic-Ristov,
Rudjer Boskovic Institute, Croatia

Reviewed by:

Vesa P. Hytönen,
University of Tampere, Finland
Birgit Leitinger,
Imperial College London,
United Kingdom

*Correspondence:

Erik H. J. Danen
e.danen@lacdr.leidenuniv.nl

Specialty section:

This article was submitted to
Cell Adhesion and Migration,
a section of the journal
Frontiers in Cell and Developmental
Biology

Received: 27 January 2022

Accepted: 16 February 2022

Published: 09 March 2022

Citation:

Bergonzini C, Kroese K, Zweemer AJM
and Danen EHJ (2022) Targeting
Integrins for Cancer Therapy -
Disappointments and Opportunities.
Front. Cell Dev. Biol. 10:863850.
doi: 10.3389/fcell.2022.863850

Integrins mediate adhesive interactions between cells and their environment, including neighboring cells and extracellular matrix (ECM). These heterodimeric transmembrane receptors bind extracellular ligands with their globular head domains and connect to the cytoskeleton through multi-protein interactions at their cytoplasmic tails. Integrin containing cell-matrix adhesions are dynamic force-responsive protein complexes that allow bidirectional mechanical coupling of cells with their environment. This allows cells to sense and modulate tissue mechanics and regulates intracellular signaling impacting on cell faith, survival, proliferation, and differentiation programs. Dysregulation of these functions has been extensively reported in cancer and associated with tumor growth, invasion, angiogenesis, metastasis, and therapy resistance. This central role in multiple hallmarks of cancer and their localization on the cell surface makes integrins attractive targets for cancer therapy. However, despite a wealth of highly encouraging preclinical data, targeting integrin adhesion complexes in clinical trials has thus far failed to meet expectations. Contributing factors to therapeutic failure are 1) variable integrin expression, 2) redundancy in integrin function, 3) distinct roles of integrins at various disease stages, and 4) sequestering of therapeutics by integrin-containing tumor-derived extracellular vesicles. Despite disappointing clinical results, new promising approaches are being investigated that highlight the potential of integrins as targets or prognostic biomarkers. Improvement of therapeutic delivery at the tumor site via integrin binding ligands is emerging as another successful approach that may enhance both efficacy and safety of conventional therapeutics. In this review we provide an overview of recent encouraging preclinical findings, we discuss the apparent disagreement between preclinical and clinical results, and we consider new opportunities to exploit the potential of integrin adhesion complexes as targets for cancer therapy.

Keywords: integrin, extracellular matrix, therapy, clinical trial, cancer

INTRODUCTION

Integrin Structure

Integrins represent a family of transmembrane adhesion receptors, facilitating the adhesive connection between cells and their surrounding extracellular matrix (ECM) or neighboring cells (Takada et al., 2007; Barczyk et al., 2009; Kadry and Calderwood, 2020). They comprise a group of heterodimeric proteins generated by non-covalent association of an α - and a β -subunit (Ginsberg, 2014). Both subunits are classified as type 1 transmembrane proteins, composed of a rather large

extracellular domain and a relatively small transmembrane- and intracellular region (Calderwood, 2004; Ginsberg, 2014). The globular head domain creates a binding site for extracellular ligands while the short cytoplasmic tails interact with a cluster of associated proteins that ultimately connects to the cytoskeleton. In total there are 18 α - and eight β -subunits, generating 24 different heterodimers, known to be expressed in humans (Calderwood, 2004). This variety in combinations allows integrins to interact with—and respond to a broad range of ligands, including insoluble ECM proteins, matricellular proteins, cell surface proteins, and soluble proteins (Alday-Parejo et al., 2019). Several recognition motifs for integrin-binding have been identified. The Arg-Gly-Asp (RGD) motif is recognized by eight different integrins and has been found in a plethora of molecules ranging from ECM proteins to growth factors to coats of microorganisms.

Integrin Function

Integrin transmembrane receptors execute two core functions: they mediate adhesion of cells to the ECM or neighboring cells, and they engage in transduction of signals received from the microenvironment. Integrin-mediated cell adhesion is dynamic: flexibility in integrin conformation allows a balance between active (open; high affinity) and inactive (closed; low affinity) states. The active state is regulated by interaction of the intracellular adaptor proteins talin and kindlin with the β -subunit cytoplasmic tail and is further stabilized by interaction with ligand at the extracellular integrin head domain (Calderwood, 2004; Sun et al., 2019). Moreover, firm cell adhesion requires integrins to cluster in cell adhesion complexes that connect to the cytoskeleton.

Integrin-mediated cell adhesion controls many aspects of cell behavior including survival, proliferation, metabolism, differentiation, as well as cell shape and motility (Huveneers and Danen, 2009). Several mechanisms of such outside-in signaling have been proposed. First, integrins allow cells to interact with the ECM in which soluble growth factors such as VEGF, TGF β and many others are concentrated, modified, and presented to cells (Hynes, 2009). Second, integrins can directly bind and activate growth factors such that they can stimulate their cognate receptors, a process currently established for activation of TGF β by α v β 6 and α v β 8 (Margadant and Sonnenberg, 2010). Third, integrin engagement and clustering can lead to local activation of receptors for soluble ligands such as EGF, PDGF, and others, often involving receptor crosstalk via Src family kinases (Ivaska and Heino, 2011; Brizzi et al., 2012). Fourth, the dynamic intracellular complex of adaptor and signaling proteins that couples integrins to the cytoskeleton allows 1) local signaling through GTPases and kinases and 2) sensing of- and responding to mechanical aspects of the microenvironment by mechanoresponsive interactions (Huveneers and Danen, 2009; Kechagia et al., 2019).

Integrins in Cancer

Dysregulation of integrin expression on cancer cells has been extensively studied in cell culture and animal models and shown to provide therapeutic opportunities for arresting tumor growth,

reducing resistance to chemo- or radiotherapy, or attenuating invasion and metastasis. Studies using genetically engineered mouse models or using human tumor cells transplanted in immune deficient mice have extensively shown that deletion of integrins in cancer cells or preventing integrin function with blocking antibodies or peptides could interfere with tumor growth, metastasis, and resistance to chemo- or radiotherapy (Juliano and Varner, 1993; Danen, 2005; Desgrosellier and Cheresh, 2010; Hamidi and Ivaska, 2018; Cooper and Giancotti, 2019). For the large family of β 1 integrins, dual roles have been identified in growth versus metastasis, indicating that caution is warranted for their application as therapeutic targets (Ramirez et al., 2011; Moran-Jones et al., 2012; Truong et al., 2014; Moritz et al., 2021). Integrins such as α v β 3, α v β 5, and α 5 β 1, are not only expressed on tumor cells but are also induced on endothelial cells during the process of angiogenesis (Friedlander et al., 1995; Avraamides et al., 2008). These integrins have indeed been shown to serve as targets for anti-angiogenic therapies in cancer, although the mode of action of anti-angiogenic drugs targeting integrins remains enigmatic (Friedlander et al., 1995; Hynes, 2002; Alavi and Cheresh, 2008; Avraamides et al., 2008).

Recent studies have added a range of novel emerging cancer-related processes that require the participation of integrins, including the establishment of a pre-metastatic niche, epithelial-to-mesenchymal transition (EMT), metabolic rewiring, cancer cell stemness and dormancy (Barkan et al., 2010; Goel et al., 2014; Seguin et al., 2015; Ata and Antonescu, 2017; Ji et al., 2020; Park and Nam, 2020; Winkler et al., 2020; Coban et al., 2021). The involvement of integrin α v β 6 in activation of TGF β was recently connected to SOX4 mediated cancer immune evasion: α v β 6 blocking antibodies could inhibit SOX4 expression and sensitize mouse models for triple negative breast cancer to T cell mediated killing in response to immune checkpoint inhibitors (Bagati et al., 2021). Integrin α v β 8, which can also activate TGF β , represents a target expressed on immune cells for modulating anti-tumor immunity. I.e., α v β 8 blocking antibodies or specific depletion of integrin α v β 8 from the surface of CD4⁺CD25⁺ regulatory T cells could attenuate TGF β mediated inhibition of CD8⁺ T cells and thereby restore tumor killing capacity of CD8⁺ T cells and synergizing with radio- or immune therapy (Dodagatta-Marri et al., 2021).

The expression of integrins on the cell-surface and their apparent role in several cancer related processes makes them appealing targets for the development of cancer therapies. However, despite the abundance of promising preclinical data, integrin targeting therapies in clinical studies have thus far largely failed to deliver. Notably, although not within the scope of this review, components of the integrin signaling complexes represent additional targets in cancer. For example, focal adhesion kinase (FAK) is overexpressed or activated in multiple cancers and supports tumor cell proliferation, migration, and therapy resistance. Small molecule inhibitors targeting FAK, such as defactinib, GSK2256098, VS-6063, and BI 853520, are currently being investigated in several clinical trials, mostly in combination with other agents (Mohanty et al., 2020; Dawson et al., 2021). Src is another interesting target associated with integrin signaling. Dasatinib, a Src inhibitor, showed

TABLE 1 | Overview of failed or terminated major clinical trials for the assessment of integrin targeting therapeutics in cancer.

Clinical trial identifier	Phase	Name therapeutic	Type therapeutic	Target integrin	Combination therapy with	Condition	Result	Mode of action
NCT01360840	II	Abituzumab (EMD525797)	Antibody	αV	—	Metastatic Castration-Resistant Prostate cancer	PFS not significantly different	Blocks cell adhesion
NCT01008475	I/II	Abituzumab (EMD525797)	Antibody	αV	Cetuximab Irinotecan	Metastatic colorectal cancer	PFS not significantly different	Blocks cell adhesion
NCT00246012	II	Intetumumab (CNTO 95)	Antibody	αV	Dacarbazine	Stage IV Melanoma	PFS not significantly different	Blocks ligand binding site
NCT00537381	II	Intetumumab (CNTO 95)	Antibody	αV	Docetaxel Prednisone	Metastatic Hormone Refractory Prostate Cancer	All efficacy endpoints better in placebo	Blocks ligand binding site
	II	Vitaxin (MEDI-523)	Antibody	$\alpha V\beta 3$	—	Metastatic cancers	No tumor regression	Blocks ligand binding site
	II	Etaracizumab (MEDI-522, Abegrin)	Antibody	$\alpha V\beta 3$	Dacarbazine	Stage IV metastatic melanoma	PFS not significantly different	Blocks ligand binding site
NCT00842712, NCT00121238, NCT00705016	II	Cilengitide (EMD 121974)	Inhibitory peptide	$\alpha V\beta 3/\alpha V\beta 5$	Multiple combinations	Multiple cancers	No benefits compared to standard of care	Blocks ligand binding site
NCT00689221	III	Cilengitide (EMD 121974)	Inhibitory peptide	$\alpha V\beta 3/\alpha V\beta 5$	Temozolomide + Radiotherapy	Newly Diagnosed Glioblastoma	Median OS not significantly different	Blocks ligand binding site
NCT00401570, NCT00654758, NCT00516841, NCT00635193, NCT00369395, NCT00100685	I/II	Volociximab (M200)	Antibody	$\alpha V\beta 1$	Alone or in combinations with standard of care	Metastatic Pancreatic Cancer, Non-Small Cell Lung Cancer, Ovarian and Peritoneal cancer, Renal cell carcinoma	Partial or no significant effects	Blocks ligand binding site
NCT00675428	II	Natalizumab	Antibody	VLA-4, ($\alpha 4$)	—	Multiple myeloma	Terminated due to low enrollment	Allosteric inhibition
NCT00131651, NCT00352313	I/II	ATN-161	Small peptide antagonist	$\alpha 5\beta 1$	Alone or in combinations	Glioma, renal cancer and other solid tumors	No therapeutic benefits	Blocks ligand binding site; prevents interaction with fibronectin synergy site
NCT01313598	I	GLPG0187	Non-peptide Integrin antagonist	Arg-Gly-Asp (RGD)-binding integrins	—	Solid tumors	No effect	Blocks ligand binding site

efficacy when combined with docetaxel in castration-resistant prostate cancer patients (Araujo et al., 2012) (NCT00439270), and was more effective than imatinib in Pediatric Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Shen et al., 2020). On the other hand, dasatinib monotherapy failed to meet expectations in patients with recurrent glioblastoma (Lassman et al., 2015) or in patients with locally advanced or stage IV mucosal,

acral, or vulvovaginal melanoma (Kalinsky et al., 2017). The challenges of targeting Src family proteins were recently reviewed by Martellucci and others (Martellucci et al., 2020). Integrins interact with many other cytoplasmic proteins, which are being investigated for their potential as therapeutic targets, however these have not yet been translated to the clinic (Cabodi et al., 2010; Bachmann et al., 2019).

In this review we focus on integrins as drug targets in cancer and discuss the apparent disagreement between preclinical and clinical results, we provide an overview of new encouraging preclinical findings and consider new opportunities to exploit the potential of integrin adhesion complexes in the effective treatment of cancer.

FINALIZED CLINICAL TRIALS EXPLORING INTEGRIN THERAPEUTICS

Monoclonal antibodies and synthetic RGD peptides have been used in clinical trials to target integrins (Li M. et al., 2021). These drugs typically block integrin function by occupying the ligand binding site. Integrin blocking antibodies previously showed efficacy in different diseases, such as multiple sclerosis, thrombosis prevention after percutaneous coronary intervention, ulcerative colitis and Chron's disease (Ley et al., 2016). Moreover, in multiple preclinical studies, inhibition of $\alpha v\beta 3$, $\alpha v\beta 5$ or $\beta 1$ integrins prevented tumor angiogenesis, reduced tumor growth and limited metastatic spread, supporting the translation of these antibodies and blocking peptides into the clinic for cancer therapy (Mitjans et al., 2000; Trikha et al., 2004; Khalili et al., 2006; Danen, 2013). Despite promising preclinical results, such therapeutics did not make it to the market. Therapeutic safety was often not the bottleneck for integrin targeting therapeutics. The major drawback was their lack of efficacy (Table 1).

The majority of integrin directed therapeutics in clinical trials involve antibodies or peptides targeting αv -integrins and these have thus far failed to show benefit for cancer patients. The integrin αv antibody abrituzumab was used in a phase II trial to treat patients with metastatic castration-resistant prostate cancer (Hussain et al., 2016) (NCT01360840). Even though a reduction in prostate cancer associated-bone lesion development was observed in the antibody treated group of patients, the primary endpoint of progression free survival (PFS) was not significantly extended. Interestingly, the addition of abrituzumab to the standard of care did show some beneficial effect on the overall survival of a subset of metastatic colorectal carcinoma patients (Élez et al., 2015; Laeufle et al., 2018) (NCT01008475). Another phase II αv -targeting study illustrated that a combination treatment of dacarbazine with the monoclonal αv -antibody intetumumab did not enhance treatment efficacy over monotreatment in patients with stage IV melanoma (O'Day et al., 2011) (NCT00246012). Testing this antibody in a phase II trial with prostate cancer patients did not improve outcome either (Heidenreich et al., 2013) (NCT00537381). Antibodies specific for $\alpha v\beta 3$ integrin have been extensively evaluated in clinical trials as well (Li M. et al., 2021). In a phase I trial, the $\alpha v\beta 3$ -antibody vitaxin failed to show benefit for patients with metastatic solid tumors (Posey et al., 2001). The additional effect of the $\alpha v\beta 3$ -antibody etaracizumab was assessed on top of dacarbazine treatment in stage IV melanoma patients (Hersey et al., 2010), however no significant differences in the time to progression (TTP) or

PFS were observed. Several phase II trials have explored efficacy of the $\alpha v\beta 3/\alpha v\beta 5$ -selective function blocking peptide cilengitide for treatment of solid tumors alone or in combination with other therapies, but results were not encouraging (Alva et al., 2012; Vermorken et al., 2014; Vansteenkiste et al., 2015; Alday-Parejo et al., 2019) (NCT00842712, NCT00121238, NCT00705016). Likewise, cilengitide failed to improve therapeutic efficacy in combination with standard of care for patients with newly diagnosed glioblastoma in a phase III trial (Stupp et al., 2014) (NCT00689221).

Other integrins that have been targeted include $\alpha 5\beta 1$. Unfortunately, phase I and II trials using the small peptide antagonist of integrin $\alpha 5\beta 1$ ATN-161 have thus far not shown benefit for glioma patients or in other solid tumors (Cianfrocca et al., 2006) (NCT00131651, NCT00352313). Similarly, the combination treatment of gemcitabine with the $\alpha 5\beta 1$ chimeric monoclonal antibody volociximab did not show any additional treatment efficacy over gemcitabine monotreatment in metastatic pancreatic cancer patients in a phase II trial (Evans et al., 2007) (NCT00401570). Moreover, volociximab efficacy was not encouraging in peritoneal, ovarian, non-small cell lung cancer or melanoma (Figlin et al., 2006; Barton, 2008; Vergote et al., 2009; Bell-McGuinn et al., 2011; Besse et al., 2013) (NCT00401570, NCT00654758, NCT00516841, NCT00635193, NCT00369395, NCT00100685). Natalizumab, an antibody targeting $\alpha 4\beta 1$ (VLA-4) has shown promising clinical results in autoimmune related diseases such as multiple sclerosis and Crohn's disease (Rudick et al., 2013; McLean and Cross, 2016). However, a phase 1/2, two-arm dose-finding study of natalizumab for relapsed or refractory Multiple Myeloma, was unfortunately terminated due to insufficient patient enrolment (NCT00675428). Among the therapeutics discussed so far, natalizumab is the only one not targeting the ligand binding site. Instead, it acts through allosteric interactions (Yu et al., 2013). Further exploring such alternative forms of integrin receptor pharmacology may lead to new and more effective treatments (Slack et al., 2022).

ONGOING CLINICAL TRIALS EXPLORING INTEGRIN THERAPEUTICS

As discussed, clinical trials of αv -integrin inhibitors or drugs targeting other integrins have thus far not been encouraging. Other approaches are now being explored in new clinical trials (Table 2).

A phase I trial aims to treat patients with previously treated pancreatic cancer or other solid tumors with the anti- $\alpha v\beta 3$ protein, ProAgio (NCT05085548). ProAgio binds $\alpha v\beta 3$ outside the classical ligand-binding site. Instead of blocking ligand binding, it triggers recruitment and activation of caspase 8, resembling a mechanism previously associated with unligated integrins (Stupack et al., 2001; Turaga et al., 2016). This may lead to apoptosis in tumor cells, endothelial cells, and cancer-associated fibroblasts with increased expression of $\alpha v\beta 3$. Subsequently, this can result in a reduction of the stroma

TABLE 2 | Overview of planned or ongoing clinical trials for the assessment of integrin targeting therapeutics in cancer.

Clinical trial identifier	Phase	Name therapeutic	Type therapeutic	Target integrin	Combination therapy with	Condition	Result
NCT05085548	I	ProAgio	Cytotoxic Protein	$\alpha V\beta 3$	—	Pancreatic cancer/Solid tumors	Recruiting
NCT04389632	I	SGN-B6A	Antibody-Drug Conjugate	$\beta 6$	—	Solid tumors	Recruiting
NCT04608812	I	OS2966	First-in-class monoclonal Ab	$\beta 1$	—	High-grade Glioma	Recruiting
NCT04508179	I	7HP349	Allosteric Integrin activation	$\alpha L\beta 2/\alpha 4\beta 1$	—	Healthy subjects	Recruiting
NCT03517176	I	CEND-1	First-in-class iRGD	αV	Gemcitabine/Nab-Paclitaxel	Pancreatic cancer	PFS

density of pancreatic cancer patients increasing access of conventional anti-cancer therapeutics to the tumor.

In a planned phase I trial, the safety, tolerability and efficacy of the integrin $\beta 6$ targeting antibody-drug conjugate SGN-B6A will be studied in patients with advanced solid tumors. SGN-B6A consists of an antibody targeting integrin $\beta 6$ conjugated with monomethyl auristatin E, an antimitotic agent that induces apoptosis by binding to tubulin (Patnaik et al., 2021) (NCT04389632). A randomized phase II trial, planned at the end of 2021 will study efficacy of a tumor penetrating iRGD peptide, CEND-1, in combination with gemcitabine and nab-paclitaxel in patients with metastatic pancreatic cancer. The first-in-class agent CEND-1 binds tumor cells and enhances delivery of co-administered anti-cancer agents. In a recently completed phase I clinical trial the safety and efficacy of CEND-1 was already explored (Dean et al., 2020; Dean et al., 2021) (NCT03517176). Based on the trial data, the combination treatment was regarded as safe. Importantly, efficacy of this treatment exceeded the efficacy of the mono-treatments, with ongoing progression free survival of some patients.


A first-in-class humanized and de-immunized monoclonal antibody, OS2966, that targets the $\beta 1$ integrin subunit is tested in patients with high-grade glioma (Nwagwu et al., 2021) (NCT04608812). Considering that OS2966 targets the entire family of $\beta 1$ containing integrins, toxicity may be an issue. Interestingly, this trial will make use of real time imaging. By adding gadolinium contrast to the OS2966 antibody, therapeutic distribution can be visualized using MRI. The additional collection of tissue specimens planned before and after treatment will provide better knowledge on the presence of any predictive biomarkers. In October 2021 a phase I trial finished, in which the safety, tolerability and pharmacokinetics (PK) of the allosteric integrin activator 7HP349 was studied in healthy male subjects (NCT04508179). Interestingly, in contrast to most integrin targeting therapeutics, this small molecule is designed to enhance integrin activity. Binding of 7HP349 should cause the activation of the $\alpha L\beta 2$ and $\alpha 4\beta 1$ integrins on immune cells, thereby enhancing an immune response. Results of this study remain to be published.

WHY HAVE INTEGRIN-TARGETED THERAPEUTICS FAILED TO ACHIEVE CLINICAL EFFICACY THUS FAR?

Despite promising preclinical *in vitro* and *in vivo* results that indicate that integrins can be targeted with good efficacy alone, or in combination with radio-, chemo-, or immune therapies, clinical results thus far do not seem encouraging (Goodman and Picard, 2012; Raab-Westphal et al., 2017; Alday-Parejo et al., 2019; Li M. et al., 2021). As with all experimental therapies, recruitment of sufficient numbers of patients fitting the trial design is a challenge. As described above, for one trial this has led to early termination. In addition, testing is often done in the context of advanced disease stages and in cases where earlier therapies have failed. Patients enrolled in the clinical trials described in **Table 1** typically have extensive treatment history with the exception of cilengitide that was explored in newly diagnosed glioblastoma patients. This may well explain the discrepancy between clinical trials and results obtained in more acute preclinical models. There are several other factors that may have negatively impacted the clinical testing of anti-integrin therapeutics in cancer. These include variable integrin expression in tumors, redundancy in integrin function, the fact that integrins can have very different roles at distinct disease stages and sequestering of therapeutics by integrin-containing tumor-derived extracellular vesicles (TEVs) (**Figure 1**).

Variable Integrin Expression and Poor Pharmacology

Thus far, antibodies have been the major type of anti-integrin therapeutics tested in clinical trials (**Table 1**). The exquisitely high specificity and corresponding low toxicity of these antibodies are most likely responsible for this high prevalence. A major limitation is a lack of knowledge with respect to expression of the target integrin in the tumor of the patient. Prior treatments may have affected integrin expression patterns in the tumor tissue. In addition, data on antibody pharmacology is generally lacking in the clinical studies. It is well known that targeting of therapeutics to the tumor tissue can be difficult due to poor vascularization, (Carmeliet



and Jain, 2011), and this may be a significant problem for the relatively large antibody drugs. Hence, it is important to determine expression of the target integrin and establish actual reach of the integrin-targeting antibodies to the tumor tissue to relate these aspects to response rates in individual patients.

Redundancy and Different Roles of Integrins at Distinct Disease Stages

Many integrins show overlap in their ligand binding spectrum. I.e., key ECM proteins present in cancer tissues such as fibronectin, laminins and collagens can be recognized by more than one integrin (Danen, 2005). Hence, the effect of blocking one integrin may be compensated for by another integrin binding the same ligand. Patients entering experimental trials often present with a mix of primary and metastatic lesions at different stages. Integrin expression has been observed to differ between primary and metastatic lesions indicating that therapies may affect one but not the other stage. e.g., expression of integrin $\alpha 2\beta 1$ was shown to promote tumor growth of a breast cancer cell line whereas $\alpha 2\beta 1$ expression was attenuated once the breast cancer cells colonized the bone (Moritz et al., 2021). In fact, integrins have been shown in some cases to have opposing roles at different stages and repress rather than support disease progression and metastasis. While depletion of $\beta 1$ integrins led to reduced outgrowth of primary tumors, it enhanced metastatic capacity in an orthotopic model using triple negative breast cancer cells

(Truong et al., 2014). Deletion of $\beta 1$ integrins also increased prostate cancer progression in a genetic mouse model (Moran-Jones et al., 2012). Likewise, specific deletion of one of the $\beta 1$ integrins, $\alpha 2\beta 1$, was demonstrated to inhibit tumor metastasis in mouse models for breast or prostate cancer (Ramirez et al., 2011; Moritz et al., 2021). Although similar examples are not described for the αv integrins targeted in clinical trials thus far, these findings suggest that therapeutic targeting of integrins may lead to complex responses in patients that may vary for individual patients.

Sequestration of Therapeutics by Integrin-Containing Extracellular Vesicles

Another mechanism that may underlie failure of anti-integrin drugs involves TEVs that have been implicated in tumor angiogenesis, immune evasion, and metastasis (Becker et al., 2016). Tumors produce more EVs with a different cargo composition (proteins, lipids and nucleic acids) as compared to normal tissues and these EVs can be derived from the tumor cells as well as other cell types in the tumor microenvironment. Integrins are expressed on TEVs, thus guiding their preference for organ colonization (Hoshino et al., 2015). As integrin expressing TEVs are released by various cancer types they may represent a common obstacle by sequestering integrin-targeting antibodies or peptides before these can reach their tumor target (Fedele et al., 2015; Hoshino et al., 2015; Singh et al., 2016; Carney et al., 2017; Krishn et al., 2019; Li et al., 2020). This concept has also been

demonstrated for patients with inflammatory bowel disease where EVs expressing integrin $\alpha 4\beta 7$ prevented vedolizumab from reaching $\alpha 4\beta 7$ expressed on T cells, which may affect therapeutic efficacy (Domenis et al., 2020).

INTEGRINS AS BIOMARKERS OF CANCER PROGRESSION

A major challenge for some of the most aggressive tumor types is providing an accurate diagnosis and prognosis for patients suffering from cancer. Integrins may serve as biomarkers in cancer, due to their aberrant expression on tumor cells and cells in the tumor microenvironment (Juliano and Varner, 1993; Danen, 2005; Desgrosellier and Cheresh, 2010; Hamidi and Ivaska, 2018; Cooper and Giancotti, 2019). Recent studies reinforce the idea that some integrins may serve as predictive cancer biomarkers.

Integrins $\alpha v\beta 3$, $\alpha v\beta 5$, and $\alpha v\beta 6$

Integrin $\alpha v\beta 3$ expression has been extensively associated with melanoma progression from an early radial growth phase to an invasive vertical growth and metastasis (Danen, 2005; Desgrosellier and Cheresh, 2010). Recently, differential expression of the integrins $\alpha v\beta 3$ and $\alpha v\beta 6$ has been observed in two subtypes of prostate cancer. Using patient derived tumor tissue and tumor bearing murine models, $\alpha v\beta 3$ was found to be largely absent in prostate adenocarcinoma ADPrCa but significantly upregulated in the more malignant primary neuroendocrine prostatic cancer (NEPrCa) and its metastatic lesions in the lung (Quaglia et al., 2021). Combined with previous findings on the role of $\alpha v\beta 3$ in the differentiation of ADPrCa to the aggressive NEPrCa, $\alpha v\beta 3$ could have potential as a biomarker in the early detection of this malignant transition in prostate cancer (Quaglia et al., 2020; Quaglia et al., 2021). The expression of integrin $\alpha v\beta 5$ has been suggested to represent a predictive biomarker for several cancer types amongst which, breast, hepatic, and gastric carcinomas (Bianchi-Smiraglia et al., 2013; Lin et al., 2018). Recently, elevated levels of $\alpha v\beta 5$ have been detected in patients suffering from either glioblastoma or colorectal carcinoma (Zhang et al., 2019; Shi et al., 2021). For both types of cancer, the overexpression of $\alpha v\beta 5$ was correlated with an unfavorable overall survival (Zhang et al., 2019; Shi et al., 2021). Integrin $\alpha v\beta 6$ has been shown to represent an unfavorable prognostic marker in pancreatic cancer patients (Li et al., 2016). This integrin was recently found to be a promising serum biomarker for patients with pancreatic cancer. Based on the identification of $\alpha v\beta 6$ in serum, chronic pancreatic (cP) patients could be distinguished from patients with pancreatic adenocarcinoma (PAC) and high serum levels of $\alpha v\beta 6$ were associated with poor survival (Lenggenhager et al., 2021). Up to now, Carbohydrate antigen CA19-9 has been the only biomarker in use for PAC, yet its sensitivity and specificity failed to meet the expectations for use as conclusive diagnostic tool (Goonetilleke and Siriwardena, 2007). A study with a larger

patient cohort will be needed to further assess the potential of $\alpha v\beta 6$ alone or in combination with CA19-9 as a prognostic serum biomarker for PAC.

Integrin $\alpha 5\beta 1$


Metastasis in the bones is often lethal in patients with mammary tumors (Coleman, 2006; Wang et al., 2019). Therefore, finding a predictive biomarker is essential for the early recognition of potentially metastasizing tumors. Integrin $\alpha 5\beta 1$ is known for its participation in tumor promoting processes like angiogenesis, proliferation and metastasis (Hamidi and Ivaska, 2018; Hou et al., 2020). In early-stage breast cancer patients, $\alpha 5\beta 1$ expression in the primary tumor was recently associated with the presence of disseminated tumor cells in bone marrow aspirates and poor metastasis-free survival (Pantano et al., 2021). The same study showed that $\alpha 5$ gene silencing or pharmacological inhibition of $\alpha 5\beta 1$ with volociximab attenuated bone colonization following intravenous injection of tumor cells in mice. Hence, stratification of breast cancer patients based on $\alpha 5\beta 1$ expression may represent a way to exploit the potential of $\alpha 5\beta 1$ antibodies, which have thus far not shown clinical benefit. Integrin $\alpha 5\beta 1$ was also found to be upregulated in several gastrointestinal tumors where enhanced expression of ITGA5 corresponded with a poor prognosis (Zhu et al., 2021). Again, these findings warrant larger scale patient studies to explore the potential of $\alpha 5\beta 1$ as a prognostic biomarker in solid tumors.

INTEGRIN MEDIATED DRUG DELIVERY

In the area of drug delivery, integrin $\alpha v\beta 3$ has been extensively pursued. It represents an attractive target because of its absence from most normal tissues versus expression in tumor tissue, including tumor cells and cells in the tumor microenvironment such as endothelial cells stimulated to undergo angiogenesis (Hood et al., 2002; Arosio and Casagrande, 2016). Integrin binding peptide motifs such as RGD, which binds $\alpha v\beta 3$ as well as other integrins, have been incorporated on the surface of drug carrying vesicles (Ruoslahti, 1996). Cyclic RGD peptides (cRGD) have gained interest in recent years given their high binding affinity for $\alpha v\beta 3$ (Li N. et al., 2021).


Liposomal (Like) Drug Carriers

Liposomal vesicles have been used extensively to reduce the toxicity of conventional anti-cancer therapeutics in healthy tissues (Allen and Cullis, 2013). Low treatment efficacy with this approach is caused by ineffective reach of the tumor. The introduction of RGD peptides on the surface of liposomal like vesicles has generally enhanced both drug accumulation in the tumor and anti-tumor efficacy of the drug in mouse models (Fu et al., 2021; Gao et al., 2021; Gong et al., 2021; Khabazian et al., 2021). Additional adjustments were made to the vesicles to further improve their drug transporting characteristics (Figure 2). Sustained drug release of the liposomes was enhanced, making use of PEGylated positively charged lipids (Khabazian et al., 2021). The cationic liposomes decorated with the cRGD peptide were then able to deliver negatively charged



siRNA into melanoma cells and effectively induce cell death (Khabazian et al., 2021). Alternatively, Gao et al. developed a double membrane vesicle (DMV), presenting not only the RGD peptide, but also lipopolysaccharides (LPS) (Gao et al., 2021). The association of LPS (normally exposed in the outer membrane of

Gram-negative bacteria) with immune cells facilitated the transit of the vesicles from the vasculature into the tumor microenvironment where it could target melanoma cells and deliver therapeutics. Other $\alpha v\beta 3$ targeting liposomal like formulations have shown a promising reduction in tumor



growth for lung and hepatocellular carcinoma in *in vivo* models (Fu et al., 2021; Gong et al., 2021). Liposomes targeting other integrins are slowly emerging, although selective expression of these integrins in tumor tissue is less evident. Modification of the liposomal membrane with the $\alpha 5\beta 1$ binding peptide PR_b, elevated the tumor specificity of the vesicle for pancreatic cancer cells (Shabana et al., 2021). The addition of a

thermosensitive and biodegradable hydrogel in the formulation enabled sustained release of the combination treatment paclitaxel and gemcitabine and attenuated pancreatic tumor growth. Other liposomes presenting the integrin $\alpha 2\beta 1$ binding ligand DGEA, were used to target breast cancer and effectively reduced tumor growth *in vivo* and enhanced the overall survival of the mice (Zhou et al., 2021).

Alternative Therapy Delivery Approaches

The use of integrins to direct anti-cancer therapeutics has not been restricted to their application in liposomal drug transport. Integrins may represent targets for the development of novel tumor selective immunotherapies (Figure 3A, B). In mouse models for breast cancer and head and neck squamous cell carcinoma, it was shown that $\alpha 6 \beta 4$ is preferentially expressed on CSCs and represents a target for immunotherapies. Vaccination with dendritic cells pulsed with $\beta 4$ peptide or adoptive transfer of T cells incubated with $\beta 4$ -CD3 bispecific antibodies, could induce T cell anti-tumor activity and inhibition of tumor growth and metastasis formation in the lungs of tumor bearing mouse models (Dobson et al., 2021). The application of covalent linking between an integrin binding peptide (mostly RGD) and an established anti-cancer therapeutic has also been explored (Figure 3D). This approach has led to reduced therapeutic-associated toxicity in healthy tissues (Cirillo and Giacomini, 2021). It will be interesting to compare toxicity profiles for this approach with those of liposomal encapsulations. Lastly, RGD peptides have also been incorporated in polydopamine (PDA) coatings to target photosensitizing agents such as gold nanostars leading to tumor specific cell death and limited adverse effects after near infrared activation of the drug (Li Y. et al., 2021) (Figure 3C).

CONCLUSIONS AND FUTURE PERSPECTIVES

Thus far, the majority of clinical trials investigating the efficacy of therapeutics targeting integrins in cancer have failed. There are several reasons for these disappointing results, including insufficient insight in the changes in expression of integrins during cancer progression in patients and a lack of knowledge concerning the pharmacological properties and accumulation at the target site of antibodies or peptides. Analysis of these aspects would have to be included in the trial design to understand reasons for failure or success. Other difficulties include the redundancy between different integrins, the different roles that integrins have been found to play at distinct disease stages and sequestration of therapeutic antibodies or peptides by integrins present on TEVs. We envision that 1) further understanding of these hurdles and

development of approaches to combat them and 2) incorporation in the trial design of analyses of integrin expression levels and drug accumulation in the tumor tissue should provide avenues for improving therapeutic strategies targeting integrins.

Integrins have been, and continue to be, explored as prognostic biomarkers in cancer, given their stage specific expression patterns. Recent studies further point to their role in distinguishing early-stage low risk-from advanced-stage high risk, metastatic disease. Also, their role as therapeutic targets continues to be investigated. Results thus far do not point to toxicity as a major issue for drugs targeting $\alpha v \beta 3$ and other αv integrins. It will be interesting to monitor the currently ongoing trials exploring $\alpha 5 \beta 1$ and αv integrins as targets in various cancers. The recent studies pointing to integrins as targets to attack CSCs, to activate anti-tumor immunity, or to synergize with drugs targeting immune checkpoints suggest exciting new possibilities in this field that await clinical translation. In addition, new strategies exploring integrins as targets for delivery of (liposomes containing) existing anticancer drugs are promising and may contribute to improved targeting of therapeutics and reduced toxicity. Indeed, several exciting possibilities await clinical testing and may well lead to a revisiting of integrins as therapeutic targets.

AUTHOR CONTRIBUTIONS

CB and KK wrote the first draft and designed figures for the manuscript. AZ and ED edited the first draft. CB, KK, AZ, and ED all read and edited subsequent drafts and read and approved the final draft.

FUNDING

This work was supported by KWF Dutch Cancer Society (grant 11957).

ACKNOWLEDGMENTS

The figures were created with BioRender.com Illustration tool.

REFERENCES

- Alavi, A. S., and Cheresh, D. A. (2008). "Integrins in Angiogenesis," Editors W. D. Figg and J. Folkman. (Boston, MA: Springer US), 63–73. doi:10.1007/978-0-387-71518-6_6In Angiogenesis: An Integrative Approach from Science To Medicine:
- Alday-Parejo, B., Stupp, R., and Rüegg, C. (2019). Are Integrins Still Practicable Targets for Anti-cancer Therapy? *Cancers (Basel)* 11. doi:10.3390/cancers11070978
- Allen, T. M., and Cullis, P. R. (2013). Liposomal Drug Delivery Systems: From Concept to Clinical Applications. *Adv. Drug Deliv. Rev.* 65 (1), 36–48. doi:10.1016/j.addr.2012.09.037

- Alva, A., Slovin, S., Daignault, S., Carducci, M., DiPaola, R., Pienta, K., et al. (2012). Phase II Study of Cilengitide (EMD 121974, NSC 707544) in Patients with Non-metastatic Castration Resistant Prostate Cancer, NCI-6735. A Study by the DOD/PCF Prostate Cancer Clinical Trials Consortium. *Invest. New Drugs* 30 (2), 749–757. doi:10.1007/s10637-010-9573-5
- Araujo, J. C., Mathew, P., Armstrong, A. J., Braud, E. L., Posadas, E., Lonberg, M., et al. (2012). Dasatinib Combined with Docetaxel for Castration-Resistant Prostate Cancer. *Cancer* 118 (1), 63–71. doi:10.1002/cncr.26204
- Arosio, D., and Casagrande, C. (2016). Advancement in Integrin Facilitated Drug Delivery. *Adv. Drug Deliv. Rev.* 97, 111–143. doi:10.1016/j.addr.2015.12.001
- Ata, R., and Antonescu, C. (2017). Integrins and Cell Metabolism: An Intimate Relationship Impacting Cancer. *Ijms* 18 (1), 189. doi:10.3390/ijms18010189

- Avraamides, C. J., Garmy-Susini, B., and Varner, J. A. (2008). Integrins in Angiogenesis and Lymphangiogenesis. *Nat. Rev. Cancer* 8 (8), 604–617. doi:10.1038/nrc2353
- Bachmann, M., Kukkurainen, S., Hytönen, V. P., and Wehrle-Haller, B. (2019). Cell Adhesion by Integrins. *Physiol. Rev.* 99 (4), 1655–1699. doi:10.1152/physrev.00036.2018
- Bagati, A., Kumar, S., Jiang, P., Pyrdol, J., Zou, A. E., Godicelj, A., et al. (2021). Integrin $\alpha\text{v}\beta 6$ -TGF β -SOX4 Pathway Drives Immune Evasion in Triple-Negative Breast Cancer. *Cancer Cell* 39 (1), 54–67. doi:10.1016/j.ccell.2020.12.001
- Barczyk, M., Carracedo, S., and Gullberg, D. (2009). Integrins. *Cell Tissue Res.* 339 (1), 269–280. doi:10.1007/s00441-009-0834-6
- Barkan, D., Green, J. E., and Chambers, A. F. (2010). Extracellular Matrix: A Gatekeeper in the Transition from Dormancy to Metastatic Growth. *Eur. J. Cancer* 46 (7), 1181–1188. doi:10.1016/j.ejca.2010.02.027
- Barton, J. (2008). A Multicenter Phase II Study of Volociximab in Patients with Relapsed Metastatic Melanoma. *J. Clin. Oncol.* 26, 9051. doi:10.1200/jco.2008.26.15
- Becker, A., Thakur, B. K., Weiss, J. M., Kim, H. S., Peinado, H., and Lyden, D. (2016). Extracellular Vesicles in Cancer: Cell-To-Cell Mediators of Metastasis. *Cancer Cell* 30 (6), 836–848. doi:10.1016/j.ccell.2016.10.009
- Bell-McGuinn, K. M., Matthews, C. M., Ho, S. N., Barve, M., Gilbert, L., Penson, R. T., et al. (2011). A Phase II, Single-Arm Study of the Anti- $\alpha 5\beta 1$ Integrin Antibody Volociximab as Monotherapy in Patients with Platinum-Resistant Advanced Epithelial Ovarian or Primary Peritoneal Cancer. *Gynecol. Oncol.* 121 (2), 273–279. doi:10.1016/j.ygyno.2010.12.362
- Besse, B., Tsao, L. C., Chao, D. T., Fang, Y., Soria, J.-C., Almokadem, S., et al. (2013). Phase Ib Safety and Pharmacokinetic Study of Volociximab, an Anti- $\alpha 5\beta 1$ Integrin Antibody, in Combination with Carboplatin and Paclitaxel in Advanced Non-small-cell Lung Cancer. *Ann. Oncol.* 24 (1), 90–96. doi:10.1093/annonc/mds281
- Bianchi-Smiraglia, A., Paesante, S., and Bakin, A. V. (2013). Integrin $\beta 5$ Contributes to the Tumorigenic Potential of Breast Cancer Cells through the Src-FAK and MEK-ERK Signaling Pathways. *Oncogene* 32 (25), 3049–3058. doi:10.1038/onc.2012.320
- Brizzi, M. F., Tarone, G., and Defilippi, P. (2012). Extracellular Matrix, Integrins, and Growth Factors as Tailors of the Stem Cell Niche. *Curr. Opin. Cell Biol.* 24 (5), 645–651. doi:10.1016/j.ccb.2012.07.001
- Cabodi, S., del Pilar Camacho-Leal, M., Di Stefano, P., and Defilippi, P. (2010). Integrin Signalling Adaptors: Not Only Figurants in the Cancer story. *Nat. Rev. Cancer* 10 (12), 858–870. doi:10.1038/nrc2967
- Calderwood, D. A. (2004). Integrin Activation. *J. Cell Sci.* 117 (5), 657–666. doi:10.1242/jcs.01014
- Carmeliet, P., and Jain, R. K. (2011). Principles and Mechanisms of Vessel Normalization for Cancer and Other Angiogenic Diseases. *Nat. Rev. Drug Discov.* 10 (6), 417–427. doi:10.1038/nrd3455
- Carney, R. P., Hazari, S., Rojalin, T., Knudson, A., Gao, T., Tang, Y., et al. (2017). Targeting Tumor-Associated Exosomes with Integrin-Binding Peptides. *Adv. Biosys.* 1 (5), 1600038. doi:10.1002/adbi.201600038
- Cianfrocca, M. E., Kimmel, K. A., Gallo, J., Cardoso, T., Brown, M. M., Hudes, G., et al. (2006). Phase 1 Trial of the Antiangiogenic Peptide ATN-161 (Ac-PhSCN-NH2), a Beta Integrin Antagonist, in Patients with Solid Tumours. *Br. J. Cancer* 94 (11), 1621–1626. doi:10.1038/sj.bjc.6603171
- Cirillo, M., and Giacomini, D. (2021). Molecular Delivery of Cytotoxic Agents via Integrin Activation. *Cancers* 13 (2), 299. doi:10.3390/cancers13020299
- Coban, B., Bergonzini, C., Zweemer, A. J. M., and Danen, E. H. J. (2021). Metastasis: Crosstalk between Tissue Mechanics and Tumour Cell Plasticity. *Br. J. Cancer* 124 (1), 49–57. doi:10.1038/s41416-020-01150-7
- Coleman, R. E. (2006). Clinical Features of Metastatic Bone Disease and Risk of Skeletal Morbidity. *Clin. Cancer Res.* 12 (20), 6243s–6249s. doi:10.1158/1078-0432.CCR-06-0931
- Cooper, J., and Giancotti, F. G. (2019). Integrin Signaling in Cancer: Mechanotransduction, Stemness, Epithelial Plasticity, and Therapeutic Resistance. *Cancer Cell* 35 (3), 347–367. doi:10.1016/j.ccell.2019.01.007
- Danen, E. H. J. (2013). Integrin Signaling as a Cancer Drug Target. *ISRN Cell Biol.* 2013, 135164. doi:10.1155/2013/135164
- Danen, E. (2005). Integrins: Regulators of Tissue Function and Cancer Progression. *Cpd* 11 (7), 881–891. doi:10.2174/1381612053381756
- Dawson, J. C., Serrels, A., Stupack, D. G., Schlaepfer, D. D., and Frame, M. C. (2021). Targeting FAK in Anticancer Combination Therapies. *Nat. Rev. Cancer* 21 (5), 313–324. doi:10.1038/s41568-021-00340-6
- Dean, A., Gill, S., McGregor, M., Broadbridge, V., Jarvelainen, H. A., and Price, T. J. (2020). 1528P Phase I Trial of the First-In-Class Agent CEND-1 in Combination with Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Pancreatic Cancer. *Ann. Oncol.* 31, S941. doi:10.1016/j.annonc.2020.08.2011
- Dean, A. P., Mulligan, F., Kelly, G., Shaughnessy, E., and Wilson, K. (2021). Updated Single Institution Outcome Data from the First-In-Human CEND-1 Trial in Metastatic Pancreatic Cancer. *Jco* 39, e16274. doi:10.1200/jco.2021.39.15_suppl.e16274
- Desgrosellier, J. S., and Cheresch, D. A. (2010). Integrins in Cancer: Biological Implications and Therapeutic Opportunities. *Nat. Rev. Cancer* 10 (1), 9–22. doi:10.1038/nrc2748
- Dobson, H. E., Ruan, S., Chang, A. E., Wicha, M. S., and Li, Q. (2021). Targeting Cancer Stem Cells via Integrin $\beta 4$. *Oncotarget* 12 (18), 1850–1858. doi:10.18632/oncotarget.27977
- Dodagatta-Marri, E., Ma, H.-Y., Liang, B., Li, J., Meyer, D. S., Chen, S.-Y., et al. (2021). Integrin $\alpha\text{v}\beta 8$ on T Cells Suppresses Anti-tumor Immunity in Multiple Models and Is a Promising Target for Tumor Immunotherapy. *Cel Rep.* 36 (1), 109309. doi:10.1016/j.celrep.2021.109309
- Domenis, R., Marino, M., Cifù, A., Scardino, G., Curcio, F., and Fabris, M. (2020). Circulating Exosomes Express $\alpha 4\beta 7$ Integrin and Compete with CD4+ T Cells for the Binding to Vedolizumab. *PLoS ONE* 15, e0242342. doi:10.1371/journal.pone.0242342
- Élez, E., Kocáková, I., Höhler, T., Martens, U. M., Bokemeyer, C., Van Cutsem, E., et al. (2015). Abituzumab Combined with Cetuximab Plus Irinotecan versus Cetuximab Plus Irinotecan Alone for Patients with KRAS Wild-type Metastatic Colorectal Cancer: the Randomised Phase I/II POSEIDON Trial. *Ann. Oncol.* 26 (1), 132–140. doi:10.1093/annonc/mdu474
- Evans, T., Ramanathan, R. K., Yazji, S., Glynne-Jones, R., Anthoney, A., Berlin, J., et al. (2007). Final Results from Cohort 1 of a Phase II Study of Volociximab, an Anti- $\alpha 5\beta 1$ Integrin Antibody, in Combination with Gemcitabine (GEM) in Patients (Pts) with Metastatic Pancreatic Cancer (MPC). *Jco* 25, 4549. doi:10.1200/jco.2007.25.18_suppl.4549
- Fedele, C., Singh, A., Zerlanko, B. J., Iozzo, R. V., and Languino, L. R. (2015). The $\alpha\text{v}\beta 6$ Integrin Is Transferred Intercellularly via Exosomes. *J. Biol. Chem.* 290 (8), 4545–4551. doi:10.1074/jbc.C114.617662
- Figlin, R. A., Kondagunta, G. V., Yazji, S., Motzer, R. J., and Bukowski, R. M. (2006). Phase II Study of Volociximab (M200), an $\alpha 5\beta 1$ Anti-integrin Antibody in Refractory Metastatic clear Cell Renal Cell Cancer (RCC). *Jco* 24, 4535. doi:10.1200/jco.2006.24.18_suppl.4535
- Friedlander, M., Brooks, P. C., Shaffer, R. W., Kincaid, C. M., Varner, J. A., and Cheresch, D. A. (1995). Definition of Two Angiogenic Pathways by Distinct α V Integrins. *Science* 270 (5241), 1500–1502. doi:10.1126/science.270.5241.1500
- Fu, S., Zhao, Y., Sun, J., Yang, T., Zhi, D., Zhang, E., et al. (2021). Integrin $\alpha\text{v}\beta 3$ -targeted Liposomal Drug Delivery System for Enhanced Lung Cancer Therapy. *Colloids Surf. B: Biointerfaces* 201, 111623. doi:10.1016/j.colsurfb.2021.111623
- Gao, J., Wang, S., Dong, X., and Wang, Z. (2021). RGD-expressed Bacterial Membrane-Derived Nanovesicles Enhance Cancer Therapy via Multiple Tumorous Targeting. *Theranostics* 11 (7), 3301–3316. doi:10.7150/thno.51988
- Ginsberg, M. H. (2014). Integrin Activation. *BMB Rep.* 47 (12), 655–659. doi:10.5483/bmbrep.2014.47.12.241
- Goel, H. L., Gritsko, T., Pursell, B., Chang, C., Shultz, L. D., Greiner, D. L., et al. (2014). Regulated Splicing of the $\alpha 6$ Integrin Cytoplasmic Domain Determines the Fate of Breast Cancer Stem Cells. *Cel Rep.* 7 (3), 747–761. doi:10.1016/j.celrep.2014.03.059
- Gong, Z., Liu, X., Zhou, B., Wang, G., Guan, X., Xu, Y., et al. (2021). Tumor Acidic Microenvironment-Induced Drug Release of RGD Peptide Nanoparticles for Cellular Uptake and Cancer Therapy. *Colloids Surf. B: Biointerfaces* 202, 111673. doi:10.1016/j.colsurfb.2021.111673
- Goodman, S. L., and Picard, M. (2012). Integrins as Therapeutic Targets. *Trends Pharmacol. Sci.* 33 (7), 405–412. doi:10.1016/j.tips.2012.04.002
- Goonetilleke, K. S., and Siriwardena, A. K. (2007). Systematic Review of Carbohydrate Antigen (CA 19-9) as a Biochemical Marker in the Diagnosis of Pancreatic Cancer. *Eur. J. Surg. Oncol. (Ejso)* 33 (3), 266–270. doi:10.1016/j.ejso.2006.10.004

- Hamidi, H., and Ivaska, J. (2018). Every Step of the Way: Integrins in Cancer Progression and Metastasis. *Nat. Rev. Cancer* 18 (9), 533–548. doi:10.1038/s41568-018-0038-z
- Heidenreich, A., Rawal, S. K., Szkarlat, K., Bogdanova, N., Dirix, L., Stenzl, A., et al. (2013). A Randomized, Double-Blind, Multicenter, Phase 2 Study of a Human Monoclonal Antibody to Human αv Integrins (Intetumumab) in Combination with Docetaxel and Prednisone for the First-Line Treatment of Patients with Metastatic Castration-Resistant Prostate Cancer. *Ann. Oncol.* 24 (2), 329–336. doi:10.1093/annonc/mds505
- Hersey, P., Sosman, J., O'Day, S., Richards, J., Bedikian, A., Gonzalez, R., et al. (2010). A Randomized Phase 2 Study of Etaracizumab, a Monoclonal Antibody against Integrin $\alpha v \beta 3$, $\pm$ Dacarbazine in Patients with Stage IV Metastatic Melanoma. *Cancer* 116 (6), 1526–1534. doi:10.1002/cncr.24821
- Hood, J. D., Bednarski, M., Frausto, R., Guccione, S., Reisfeld, R. A., Xiang, R., et al. (2002). Tumor Regression by Targeted Gene Delivery to the Neovasculature. *Science* 296 (5577), 2404–2407. doi:10.1126/science.1070200
- Hoshino, A., Costa-Silva, B., Shen, T.-L., Rodrigues, G., Hashimoto, A., Tesic Mark, M., et al. (2015). Tumour Exosome Integrins Determine Organotropic Metastasis. *Nature* 527 (7578), 329–335. doi:10.1038/nature15756
- Hou, J., Yan, D., Liu, Y., Huang, P., and Cui, H. (2020). The Roles of Integrin $\alpha 5 \beta 1$ in Human Cancer. *Ott* 13, 13329–13344. doi:10.2147/OTT.S273803
- Hussain, M., Le Moulec, S., Gimmi, C., Bruns, R., Straub, J., and Miller, K. (2016). Differential Effect on Bone Lesions of Targeting Integrins: Randomized Phase II Trial of Abituzumab in Patients with Metastatic Castration-Resistant Prostate Cancer. *Clin. Cancer Res.* 22 (13), 3192–3200. doi:10.1158/1078-0432.CCR-15-2512
- Huveneers, S., and Danen, E. H. J. (2009). Adhesion Signaling - Crosstalk between Integrins, Src and Rho. *J. Cel Sci.* 122 (8), 1059–1069. doi:10.1242/jcs.039446
- Hynes, R. O. (2002). A Reevaluation of Integrins as Regulators of Angiogenesis. *Nat. Med.* 8 (9), 918–921. doi:10.1038/nm0902-918
- Hynes, R. O. (2009). The Extracellular Matrix: Not Just Pretty Fibrils. *Science* 326 (5957), 1216–1219. doi:10.1126/science.1176009
- Ivaska, J., and Heino, J. (2011). Cooperation between Integrins and Growth Factor Receptors in Signaling and Endocytosis. *Annu. Rev. Cel Dev. Biol.* 27 (1), 291–320. doi:10.1146/annurev-cellbio-092910-154017
- Ji, Q., Zhou, L., Sui, H., Yang, L., Wu, X., Song, Q., et al. (2020). Primary Tumors Release ITGBL1-Rich Extracellular Vesicles to Promote Distal Metastatic Tumor Growth through Fibroblast-Niche Formation. *Nat. Commun.* 11 (1), 1211. doi:10.1038/s41467-020-14869-x
- Juliano, R., and Varner, J. (1993). Adhesion Molecules in Cancer: the Role of Integrins. *Curr. Opin. Cel Biol.* 5 (5), 812–818. doi:10.1016/0955-0674(93)90030-T
- Kadry, Y. A., and Calderwood, D. A. (2020). Chapter 22: Structural and Signaling Functions of Integrins. *Biochim. Biophys. Acta (Bba) - Biomembranes* 1862 (5), 183206. doi:10.1016/j.bbmem.2020.183206
- Kalinsky, K., Lee, S., Rubin, K. M., Lawrence, D. P., Iafrate, A. J., Borger, D. R., et al. (2017). A Phase 2 Trial of Dasatinib in Patients with Locally Advanced or Stage IV Mucosal, Acral, or Vulvovaginal Melanoma: A Trial of the ECOG-ACRIN Cancer Research Group (E2607). *Cancer* 123 (14), 2688–2697. doi:10.1002/cncr.30663
- Kechagia, J. Z., Ivaska, J., and Roca-Cusachs, P. (2019). Integrins as Biomechanical Sensors of the Microenvironment. *Nat. Rev. Mol. Cel Biol.* 20 (8), 457–473. doi:10.1038/s41580-019-0134-2
- Khabazian, E., Vakhshiteh, F., Norouzi, P., Fatahi, Y., Dinarvand, R., and Atyabi, F. (2021). Cationic Liposome Decorated with Cyclic RGD Peptide for Targeted Delivery of Anti-STAT3 siRNA to Melanoma Cancer Cells. *J. Drug Target.* 1–34. doi:10.1080/1061186X.2021.1973481
- Khalili, P., Arakelian, A., Chen, G., Plunkett, M. L., Beck, I., Parry, G. C., et al. (2006). A Non-RGD-based Integrin Binding Peptide (ATN-161) Blocks Breast Cancer Growth and Metastasis *In Vivo*. *Mol. Cancer Ther.* 5 (9), 2271–2280. doi:10.1158/1535-7163.MCT-06-0100
- Krishn, S. R., Singh, A., Bowler, N., Duffy, A. N., Friedman, A., Fedele, C., et al. (2019). Prostate Cancer Sheds the $\alpha v \beta 3$ Integrin *In Vivo* through Exosomes. *Matrix Biol.* 77, 41–57. doi:10.1016/j.matbio.2018.08.004
- Laeufle, R., Arnold, D., Kopetz, S., Straub, J., Bruns, R., Massimini, G., et al. (2018). Patient Selection for Targeting Integrin with Abituzumab in Patients with Metastatic Colorectal Cancer (mCRC): A Retrospective Analysis of the Randomized Phase I/II Poseidon Study. *Ann. Oncol.* 29, viii164. doi:10.1093/annonc/mdy281.035
- Lassman, A. B., Pugh, S. L., Gilbert, M. R., Aldape, K. D., Geinoz, S., Beumer, J. H., et al. (2015). Phase 2 Trial of Dasatinib in Target-Selected Patients with Recurrent Glioblastoma (RTOG 0627). *Neuro. Oncol.* 17 (7), 992–998. doi:10.1093/neuonc/nov011
- Lenggenhager, D., Bengs, S., Fritsch, R., Hussung, S., Busenhardt, P., Endhardt, K., et al. (2021). $\beta 6$ -Integrin Serves as a Potential Serum Marker for Diagnosis and Prognosis of Pancreatic Adenocarcinoma. *Clin. Transl. Gastroenterol.* 12, e00395. doi:10.14309/ctg.0000000000000395
- Ley, K., Rivera-Nieves, J., Sandborn, W. J., and Shattil, S. (2016). Integrin-based Therapeutics: Biological Basis, Clinical Use and New Drugs. *Nat. Rev. Drug Discov.* 15 (3), 173–183. doi:10.1038/nrd.2015.10
- Li, M., Wang, Y., Li, M., Wu, X., Settrahmane, S., and Xu, H. (2021a). Integrins as Attractive Targets for Cancer Therapeutics. *Acta Pharmaceutica Sinica B* 11 (9), 2726–2737. doi:10.1016/j.apsb.2021.01.004
- Li, N., Qiu, S., Fang, Y., Wu, J., and Li, Q. (2021b). Comparison of Linear vs. Cyclic RGD Pentapeptide Interactions with Integrin $\alpha v \beta 3$ by Molecular Dynamics Simulations. *Biology* 10 (7), 688. doi:10.3390/biology10070688
- Li, X., Tang, M., Zhu, Q., Wang, X., Lin, Y., and Wang, X. (2020). The Exosomal Integrin $\alpha 5 \beta 1$ /AEP Complex Derived from Epithelial Ovarian Cancer Cells Promotes Peritoneal Metastasis through Regulating Mesothelial Cell Proliferation and Migration. *Cell Oncol.* 43 (2), 263–277. doi:10.1007/s13402-019-00486-4
- Li, Y., Hu, P., Wang, X., Hou, X., Liu, F., and Jiang, X. (2021c). Integrin $\alpha v \beta 3$ -targeted Polydopamine-Coated Gold Nanostars for Photothermal Ablation Therapy of Hepatocellular Carcinoma. *Regen. Biomater.* 8, rbab046. doi:10.1093/rb/rbab046
- Li, Z., Lin, P., Gao, C., Peng, C., Liu, S., Gao, H., et al. (2016). Integrin $\beta 6$ Acts as an Unfavorable Prognostic Indicator and Promotes Cellular Malignant Behaviors via ERK-ETS1 Pathway in Pancreatic Ductal Adenocarcinoma (PDAC). *Tumor Biol.* 37 (4), 5117–5131. doi:10.1007/s13277-015-4353-7
- Lin, Z., He, R., Luo, H., Lu, C., Ning, Z., Wu, Y., et al. (2018). Integrin- $\beta 5$, a miR-185-Targeted Gene, Promotes Hepatocellular Carcinoma Tumorigenesis by Regulating β -catenin Stability. *J. Exp. Clin. Cancer Res.* 37 (1), 17. doi:10.1186/s13046-018-0691-9
- Margadant, C., and Sonnenberg, A. (2010). Integrin-TGF- β Crosstalk in Fibrosis, Cancer and Wound Healing. *EMBO Rep.* 11 (2), 97–105. doi:10.1038/embor.2009.276
- Martellucci, S., Clementi, L., Sabetta, S., Mattei, V., Botta, L., and Angelucci, A. (2020). Src Family Kinases as Therapeutic Targets in Advanced Solid Tumors: What We Have Learned So Far. *Cancers* 12 (6), 1448. doi:10.3390/cancers12061448
- McLean, L. P., and Cross, R. K. (2016). Integrin Antagonists as Potential Therapeutic Options for the Treatment of Crohn's Disease. *Expert Opin. Investig. Drugs* 25 (3), 263–273. doi:10.1517/13543784.2016.1148137
- Mitjans, F., Meyer, T., Fittschen, C., Goodman, S., Jonczyk, A., Marshall, J. F., et al. (2000). *In Vivo* therapy of Malignant Melanoma by Means of Antagonists of αv Integrins. *Int. J. Cancer* 87 (5), 716–723. doi:10.1002/1097-0215(20000901)87:5<716::aid-ijc14>3.0.co;2-r
- Mohanty, A., Pharaon, R. R., Nam, A., Salgia, S., Kulkarni, P., and Massarelli, E. (2020). FAK-targeted and Combination Therapies for the Treatment of Cancer: an Overview of Phase I and II Clinical Trials. *Expert Opin. Investig. Drugs* 29 (4), 399–409. doi:10.1080/13543784.2020.1740680
- Moran-Jones, K., Ledger, A., and Naylor, M. J. (2012). $\beta 1$ Integrin Deletion Enhances Progression of Prostate Cancer in the TRAMP Mouse Model. *Sci. Rep.* 2 (1), 526. doi:10.1038/srep00526
- Moritz, M. N. O., Merkel, A. R., Feldman, E. G., and Seliestre-de-Araujo, H. S. (2021). Rhoades (Sterling), J.A.Biphasic $\alpha 2 \beta 1$ Integrin Expression in Breast Cancer Metastasis to Bone. *Int. J. Mol. Sci.* 22. doi:10.3390/ijms22136906
- Nwagwu, C. D., Immidisetti, A. V., Bukanowska, G., Vogelbaum, M. A., and Carbonell, A.-M. (2021). Convection-Enhanced Delivery of a First-In-Class Anti- $\beta 1$ Integrin Antibody for the Treatment of High-Grade Glioma Utilizing Real-Time Imaging. *Pharmaceutics* 13. doi:10.3390/pharmaceutics13010040
- O'Day, S., Pavlick, A., Pavlick, A., Loquai, C., Lawson, D., Gutzmer, R., et al. (2011). A Randomised, Phase II Study of Intetumumab, an Anti- αv -integrin mAb, Alone and with Dacarbazine in Stage IV Melanoma. *Br. J. Cancer* 105 (3), 346–352. doi:10.1038/bjc.2011.183

- Pantano, F., Croset, M., Driouch, K., Bednarz-Knoll, N., Iuliani, M., Ribelli, G., et al. (2021). Integrin Alpha5 in Human Breast Cancer Is a Mediator of Bone Metastasis and a Therapeutic Target for the Treatment of Osteolytic Lesions. *Oncogene* 40 (7), 1284–1299. doi:10.1038/s41388-020-01603-6
- Park, S.-Y., and Nam, J.-S. (2020). The Force Awakens: Metastatic Dormant Cancer Cells. *Exp. Mol. Med.* 52 (4), 569–581. doi:10.1038/s12276-020-0423-z
- Patnaik, A., Calvo, E., Piha-Paul, S. A. A., Hollebecque, A., Galvao, V., Lopez, J. S., et al. (2021). A Phase I Study of SGN-B6a, an Antibody-Drug Conjugate Targeting Integrin Beta-6, in Patients with Advanced Solid Tumors (SGNB6A-001, Trial in Progress)(15_suppl). *J. Clin. Oncol.* 39, TPS3144. doi:10.1200/JCO.2021.39.15_suppl.TPS3144
- Posey, J. A., Khazaeli, M. B., DelGrosso, A., Saleh, M. N., Lin, C. Y., Huse, W., et al. (2001). A Pilot Trial of Vitaxin, A Humanized Anti-vitronectin Receptor (Anti α v β 3) Antibody in Patients with Metastatic Cancer. *Cancer Biother. Radiopharm.* 16 (2), 125–132. doi:10.1089/108497801300189218
- Quaglia, F., Krishn, S. R., Daaboul, G. G., Sarker, S., Pippa, R., Domingo-Domenech, J., et al. (2020). Small Extracellular Vesicles Modulated by α v β 3 Integrin Induce Neuroendocrine Differentiation in Recipient Cancer Cells. *J. Extracellular Vesicles* 9 (1), 1761072. doi:10.1080/20013078.2020.1761072
- Quaglia, F., Krishn, S. R., Wang, Y., Goodrich, D. W., McCue, P., Kossenkova, A. V., et al. (2021). Differential Expression of α v β 3 and α v β 6 Integrins in Prostate Cancer Progression. *PLoS ONE* 16, e0244985. doi:10.1371/journal.pone.0244985
- Raab-Westphal, S., Marshall, J. F., and Goodman, S. L. (2017). Integrins as Therapeutic Targets: Successes and Cancers. *Cancers (Basel)* 9. doi:10.3390/cancers9090110
- Ramirez, N. E., Zhang, Z., Madamanchi, A., Boyd, K. L., O'Rear, L. D., Nashabi, A., et al. (2011). The α 2 β 1 Integrin Is a Metastasis Suppressor in Mouse Models and Human Cancer. *J. Clin. Invest.* 121 (1), 226–237. doi:10.1172/JCI42328
- Rudick, R., Polman, C., Clifford, D., Miller, D., and Steinman, L. (2013). Natalizumab. *JAMA Neurol.* 70 (2), 172–182. doi:10.1001/jamaneurol.2013.598
- Ruoslahti, E. (1996). RGD and Other Recognition Sequences for Integrins. *Annu. Rev. Cell Dev. Biol.* 12 (1), 697–715. doi:10.1146/annurev.cellbio.12.1.697
- Seguin, L., Desgrosellier, J. S., Weis, S. M., and Chersesh, D. A. (2015). Integrins and Cancer: Regulators of Cancer Stemness, Metastasis, and Drug Resistance. *Trends Cell Biol.* 25 (4), 234–240. doi:10.1016/j.tcb.2014.12.006
- Shabana, A. M., Kambhampati, S. P., Hsia, R.-c., Kannan, R. M., and Kokkoli, E. (2021). Thermosensitive and Biodegradable Hydrogel Encapsulating Targeted Nanoparticles for the Sustained Co-delivery of Gemcitabine and Paclitaxel to Pancreatic Cancer Cells. *Int. J. Pharmaceutics* 593, 120139. doi:10.1016/j.ijpharm.2020.120139
- Shen, S., Chen, X., Cai, J., Yu, J., Gao, J., Hu, S., et al. (2020). Effect of Dasatinib vs Imatinib in the Treatment of Pediatric Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. *JAMA Oncol.* 6 (3), 358–366. doi:10.1001/jamaoncol.2019.5868
- Shi, W., He, J., Huang, Y., Zeng, Z., Feng, Z., Xu, H., et al. (2021). Integrin β 5 Enhances the Malignancy of Human Colorectal Cancer by Increasing the TGF- β Signaling. *Anticancer Drugs* 32 (7), 717–726. doi:10.1097/CAD.0000000000001050
- Singh, A., Fedele, C., Lu, H., Nevalainen, M. T., Keen, J. H., and Languino, L. R. (2016). Exosome-mediated Transfer of α v β 3 Integrin from Tumorigenic to Nontumorigenic Cells Promotes a Migratory Phenotype. *Mol. Cancer Res.* 14 (11), 1136–1146. doi:10.1158/1541-7786.MCR-16-0058
- Slack, R. J., Macdonald, S. J. F., Roper, J. A., Jenkins, R. G., and Hatley, R. J. D. (2022). Emerging Therapeutic Opportunities for Integrin Inhibitors. *Nat. Rev. Drug Discov.* 21 (1), 60–78. doi:10.1038/s41573-021-00284-4
- Stupack, D. G., Puente, X. S., Boutsaboualy, S., Storgard, C. M., and Chersesh, D. A. (2001). Apoptosis of Adherent Cells by Recruitment of Caspase-8 to Unligated Integrins. *J. Cell Biol.* 155 (3), 459–470. doi:10.1083/jcb.200106070
- Stupp, R., Hegi, M. E., Gorlia, T., Erridge, S. C., Perry, J., Hong, Y.-K., et al. (2014). Cilengitide Combined with Standard Treatment for Patients with Newly Diagnosed Glioblastoma with Methylated MGMT Promoter (CENTRIC EORTC 26071-22072 Study): a Multicentre, Randomised, Open-Label, Phase 3 Trial. *Lancet Oncol.* 15 (10), 1100–1108. doi:10.1016/S1473-2045(14)70379-1
- Sun, Z., Costell, M., and Fässler, R. (2019). Integrin Activation by Talin, Kindlin and Mechanical Forces. *Nat. Cell Biol.* 21 (1), 25–31. doi:10.1038/s41556-018-0234-9
- Takada, Y., Ye, X., and Simon, S. (2007). The Integrins. *Genome Biol.* 8 (5), 215. doi:10.1186/gb-2007-8-5-215
- Trikha, M., Zhou, Z., Nemeth, J. A., Chen, Q., Sharp, C., Emmell, E., et al. (2004). CNTO 95, a Fully Human Monoclonal Antibody that Inhibits α v Integrins, Has Antitumor and Antiangiogenic Activity in Vivo. *Int. J. Cancer* 110 (3), 326–335. doi:10.1002/ijc.20116
- Truong, H., Xiong, J., Ghotra Veerander, P. S., Nirmala, E., Haazen, L., Le Dévédec Sylvia, E., et al. (2014). β 1 Integrin Inhibition Elicits a Prometastatic Switch through the TGF β -miR-200-ZEB Network in E-Cadherin-Positive Triple-Negative Breast Cancer. *Sci. Signal.* 7, ra15. doi:10.1126/scisignal.2004751
- Turaga, R. C., Yin, L., Yang, J. J., Lee, H., Ivanov, I., Yan, C., et al. (2016). Rational Design of a Protein that Binds Integrin α v β 3 outside the Ligand Binding Site. *Nat. Commun.* 7 (1), 11675. doi:10.1038/ncomms11675
- Vansteenkiste, J., Barlesi, F., Waller, C. F., Bannouna, J., Gridelli, C., Goekkurt, E., et al. (2015). Cilengitide Combined with Cetuximab and Platinum-Based Chemotherapy as First-Line Treatment in Advanced Non-small-cell Lung Cancer (NSCLC) Patients: Results of an Open-Label, Randomized, Controlled Phase II Study (CERTO). *Ann. Oncol.* 26 (8), 1734–1740. doi:10.1093/annonc/mdv219
- Vergote, I. B., Colombo, N., Kutarska, E., Del Campo, J., Pippitt, C., Casado, A., et al. (2009). Phase II Study Comparing Volociximab (An Antiangiogenic Antibody) and Pegylated Liposomal Doxorubicin (PLD) with PLD Alone in Recurrent Ovarian or Primary Peritoneal Cancer. *Jco* 27, 5560. doi:10.1200/jco.2009.27.15_suppl.5560
- Vermorken, J. B., Peyrade, F., Krauss, J., Mesia, R., Remenar, E., Gauler, T. C., et al. (2014). Cisplatin, 5-fluorouracil, and Cetuximab (PFE) with or without Cilengitide in Recurrent/metastatic Squamous Cell Carcinoma of the Head and Neck: Results of the Randomized Phase I/II ADVANTAGE Trial (Phase II Part). *Ann. Oncol.* 25 (3), 682–688. doi:10.1093/annonc/mdu003
- Wang, R., Zhu, Y., Liu, X., Liao, X., He, J., and Niu, L. (2019). The Clinicopathological Features and Survival Outcomes of Patients with Different Metastatic Sites in Stage IV Breast Cancer. *BMC Cancer* 19 (1), 1091. doi:10.1186/s12885-019-6311-z
- Winkler, J., Abisoye-Ogunniyan, A., Metcalf, K. J., and Werb, Z. (2020). Concepts of Extracellular Matrix Remodelling in Tumour Progression and Metastasis. *Nat. Commun.* 11 (1), 5120. doi:10.1038/s41467-020-18794-x
- Yu, Y., Schürpf, T., and Springer, T. A. (2013). How Natalizumab Binds and Antagonizes α 4 Integrins. *J. Biol. Chem.* 288 (45), 32314–32325. doi:10.1074/jbc.M113.501668
- Zhang, L.-Y., Guo, Q., Guan, G.-F., Cheng, W., Cheng, P., and Wu, A.-h. (2019). Integrin Beta 5 Is a Prognostic Biomarker and Potential Therapeutic Target in Glioblastoma. *Front. Oncol.* 9, 904. doi:10.3389/fonc.2019.00904
- Zhou, B., Li, M., Xu, X., Yang, L., Ye, M., Chen, Y., et al. (2021). Integrin α 2 β 1 Targeting DGEA-Modified Liposomal Doxorubicin Enhances Antitumor Efficacy against Breast Cancer. *Mol. Pharmaceutics* 18 (7), 2634–2646. doi:10.1021/acs.molpharmaceut.1c00132
- Zhu, H., Wang, G., Zhu, H., and Xu, A. (2021). ITGA5 Is a Prognostic Biomarker and Correlated with Immune Infiltration in Gastrointestinal Tumors. *BMC Cancer* 21 (1), 269. doi:10.1186/s12885-021-07996-1

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Bergonzini, Kroese, Zweemer and Danen. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.